Welcome to our dedicated page for Intelligent Bio Solutions SEC filings (Ticker: INBS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Intelligent Bio Solutions Inc. (INBS) SEC filings page on Stock Titan provides centralized access to the company’s regulatory disclosures filed with the U.S. Securities and Exchange Commission. As a Nasdaq-listed medical technology issuer, Intelligent Bio Solutions uses these filings to report financial results, corporate actions, governance matters and material events related to its non-invasive drug screening and testing solutions.
Investors researching INBS can review annual reports on Form 10-K and quarterly reports on Form 10-Q for detailed discussions of the company’s business, risk factors, financial statements and segment information. These periodic reports describe the Intelligent Fingerprinting Drug Screening System, the company’s consumables-focused revenue model, geographic reach and customer segments in sectors such as construction, manufacturing and engineering, transport and logistics, mining, drug treatment organizations and coroners.
The company also files numerous Form 8-K current reports covering specific developments. Recent 8-K filings describe preliminary and final revenue results, record quarterly revenue driven by cartridge sales, the extension of warrant termination dates, new customer account additions, and updates on regulatory timelines for FDA 510(k) clearance of the Intelligent Fingerprinting Drug Screening System. Other 8-Ks detail stockholder meeting outcomes, amendments to the 2019 Long Term Incentive Plan, and the approval and implementation of a 1-for-10 reverse stock split effective December 15, 2025.
Listing-related disclosures appear in filings that discuss Nasdaq bid price compliance, including the December 15, 2025 deficiency letter noting that the company’s closing bid price had been below $1.00 per share for 30 consecutive business days and granting an initial 180-day compliance period. Additional filings describe equity and warrant transactions, such as private placements and warrant inducement arrangements submitted for stockholder approval under Nasdaq rules.
On Stock Titan, these documents are supplemented with AI-powered summaries that highlight key points from lengthy 10-K, 10-Q and 8-K filings, helping readers quickly understand topics like revenue trends, capital structure changes, equity incentive plan amendments and regulatory updates. Users can also locate information relevant to insider and equity-linked activity by reviewing warrant-related disclosures and stock-based compensation plans discussed in proxy statements and current reports.
By using this INBS filings page, investors and analysts can efficiently monitor how Intelligent Bio Solutions communicates its financial condition, strategic initiatives, governance decisions and listing status to regulators and the market, without needing to manually parse each full-length SEC document.
Intelligent Bio Solutions Inc. preliminary proxy excerpt discloses governance and compensation policies for executives and directors. The company has an Insider Trading Policy that prohibits hedging transactions and requires compliance with securities laws. A clawback/recoupment policy applies to incentive-based compensation for executive officers in the event of a required financial restatement, covering awards received after October 2, 2023, and looking back three completed fiscal years plus certain transition periods.
The document shows director and named executive officer compensation items and totals for 2024 and 2025 (examples: Spiro Sakiris total compensation figures of $446,622 in 2024 and $363,532 in 2025; other individual director fees like $51,250, $50,625, $55,625). It outlines an equity compensation plan (2019 Plan) with current shares reserved and available: 7,154,982 securities reserved for outstanding options/warrants/rights, 100,000,000 shares authorized, and available shares under the plan of 1,192,655 (if Proposal 3 not approved) or 1,687,655 (if approved). A proposed Reverse Stock Split amendment is described as subject to shareholder approval, with the Board to fix the ratio within the approved range. A 9.99% holder is identified: Alyeska Master Fund, LP (921,825 shares).
The prospectus fragment for Intelligent Bio Solutions Inc. (INBS) discloses that the Series J Warrants have an initial exercise price of $1.90 per share, expire 5.5 years after issuance, and would convert into up to 4,046,456 shares of common stock if exercised. Exercise is conditioned on the Company receiving stockholder approval. The filing also lists key executives and directors, including CEO Harry Simeonidis and CFO Spiro Sakiris. The provided text appears partial and lacks broader financial data.
Intelligent Bio Solutions, Inc. filed an S-3 shelf registration describing ownership and disclosure exhibits. The filing lists significant holders including Alyeska Master Fund, LP with 1,758,240 shares (16.99%), CVI Investments, Inc. with 1,421,556 shares (13.74%), and Warberg WF XII LP with 1,279,120 shares (12.65%). Several other institutional and insider holdings are reported with percentages or ‘‘*’’ denoting de minimis amounts. The filing references a Form 8-A originally filed December 22, 2020, and identifies SEC registration fee of $919.16, accounting fees of $5,000.00, and a total listed as $25,919.16. The document is signed by the CEO, CFO, Chairman, and multiple directors with signature dates of August 22, 2025.
Intelligent Bio Solutions Inc. filed a current report to disclose that it issued a press release on August 15, 2025 announcing its financial results for the three months and full fiscal year ended June 30, 2025. The press release is attached as Exhibit 99.1.
The company states that the information in this report and the exhibit is being furnished, not filed, so it is not subject to certain liability provisions under U.S. securities laws and will not be incorporated into other filings unless specifically referenced.
Intelligent Bio Solutions Inc. (INBS) reported operating results and disclosures in its Form 10-K showing continued commercial rollout of its Intelligent Fingerprinting (IFP) products and persistent losses that raise near-term financing risk. The company installed over 1,000 IFP readers, added 115 new customer accounts, launched localized websites in Arabic, Italian and Spanish, was granted a U.S. patent for its drug screening cartridge, and completed a pharmacokinetic study supporting a 510(k) submission (Dec 2024) for codeine detection.
Financially, revenue line items include reader sales of $711,737 (FY2025) with GAAP gross profit of $1,246,859. The company recorded a net loss of $10,604,886, shareholders' equity of $2,813,824, a working capital deficit of $1,212,419, and an accumulated deficit of $62,533,065. Management discloses an explanatory audit paragraph on its ability to continue as a going concern and states it will need to raise additional capital within twelve months.
Intelligent Bio Solutions, Inc. (INBS) filed a Form D reporting a Regulation D, Rule 506(b) offering in which the issuer raised $3,839,356. The filing shows the total amount offered equaled the amount sold, with